Credit Suisse’s Matinas BioPharma MTNB Stock Holding History

Credit Suisse’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-484	Closed	-$19K	–	4088
2018 Q1	$19K	Buy	484 +112	+30%	+$5.92K	﹤0.01%	3926
2017 Q4	$22K	Sell	372 -319	-46%	-$20.5K	﹤0.01%	3939
2017 Q3	$46K	Buy	691 +464	+204%	+$31K	﹤0.01%	4142
2017 Q2	$19K	Sell	227 -194	-46%	-$26K	﹤0.01%	3808
2017 Q1	$58K	Buy	+421	New	+$68.7K	﹤0.01%	3737

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

Credit Suisse's MTNB Position: Q2 2018 in Review

Credit Suisse sold out of Matinas BioPharma (MTNB) in Q2 2018, closing a stake of 484 shares — an estimated $19K sold.

Credit Suisse first reported a position in MTNB in Q1 2017 and held it in 5 quarters. The position peaked at $58K in Q1 2017. 39 funds tracked by Wall St. Rank hold MTNB as of Q2 2018.

Credit Suisse reported no remaining Matinas BioPharma position as of Q2 2018 after selling out during the quarter.
Credit Suisse sold 484 Matinas BioPharma shares in Q2 2018, an estimated $19K.
Credit Suisse first reported a position in Matinas BioPharma in Q1 2017 and held it in 5 quarters.
Credit Suisse's Matinas BioPharma position peaked at $58K in Q1 2017.
39 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2018.

Based on Credit Suisse's 13F filing for Q2 2018, filed 14 Aug 2018.